Evaluating the impact of unmeasured confounding with internal validation data: an example cost evaluation in type 2 diabetes.
暂无分享,去创建一个
Karen Price | John W. Seaman | Douglas Faries | Xiaomei Peng | Manjiri Pawaskar | James D. Stamey | Karen L. Price | J. Seaman | J. Stamey | D. Faries | M. Pawaskar | X. Peng
[1] R. Heine,et al. Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes , 2005, Annals of Internal Medicine.
[2] Ralph B D'Agostino,et al. Estimating treatment effects using observational data. , 2007, JAMA.
[3] Jan P Vandenbroucke,et al. Observational Research, Randomised Trials, and Two Views of Medical Science , 2008, PLoS medicine.
[4] S. Schneeweiss,et al. Assessing Residual Confounding of the Association between Antipsychotic Medications and Risk of Death using Survey Data , 2009, CNS drugs.
[5] R. D'Agostino. Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .
[6] R. D'Agostino. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. , 2005, Statistics in medicine.
[7] Paul Gustafson,et al. Probabilistic Approaches to Better Quantifying the Results of Epidemiologic Studies , 2010, International journal of environmental research and public health.
[8] R. Ness,et al. Periconceptional multivitamin use reduces the risk of preeclampsia. , 2006, American journal of epidemiology.
[9] Douglas E. Faries,et al. Analysis of Observational Health Care Data Using SAS , 2010 .
[10] J. Robins,et al. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.
[11] Lawrence C McCandless,et al. A sensitivity analysis using information about measured confounders yielded improved uncertainty assessments for unmeasured confounding. , 2008, Journal of clinical epidemiology.
[12] A. Hartz,et al. A comparison of observational studies and randomized, controlled trials. , 2000, The New England journal of medicine.
[13] Lizheng Shi,et al. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis , 2011, Journal of medical economics.
[14] Peter Davey,et al. A checklist for retrospective database studies--report of the ISPOR Task Force on Retrospective Databases. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[15] S. Schneeweiss. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.
[16] P. Gustafson,et al. Bayesian sensitivity analysis for unmeasured confounding in observational studies , 2007, Statistics in medicine.
[17] G. Oster,et al. Lifetime health and economic benefits of weight loss among obese persons. , 1999, American journal of public health.
[18] David E. Booth,et al. Analysis of Incomplete Multivariate Data , 2000, Technometrics.
[19] J. Trogdon,et al. Nationally Representative Medical Costs of Diabetes by Time Since Diagnosis , 2008, Diabetes Care.
[20] D. Rubin,et al. Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .
[21] Til Stürmer,et al. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. , 2005, American journal of epidemiology.
[22] B. Hoogwerf,et al. Effects of Exenatide on Diabetes, Obesity, Cardiovascular Risk Factors, and Hepatic Biomarkers in Patients with Type 2 Diabetes , 2008, Journal of diabetes science and technology.
[23] Jalpa A Doshi,et al. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[24] Anirban Basu,et al. Generalized Modeling Approaches to Risk Adjustment of Skewed Outcomes Data , 2003, Journal of health economics.
[25] H. Birnbaum,et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data , 2007, Current medical research and opinion.
[26] Til Stürmer,et al. Performance of propensity score calibration--a simulation study. , 2007, American journal of epidemiology.
[27] Comparison of several imputation methods for missing baseline data in propensity scores analysis of binary outcome. , 2010, Pharmaceutical statistics.
[28] J. Concato,et al. Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.
[29] R. Willke,et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[30] J. Walkup,et al. Studying Prescription Drug Use and Outcomes With Medicaid Claims Data: Strengths, Limitations, and Strategies , 2007, Medical care.
[31] S. Schneeweiss,et al. Claims Data Studies of Sedative‐Hypnotics and Hip Fractures in Older People: Exploring Residual Confounding Using Survey Information , 2005, Journal of the American Geriatrics Society.